Johns Hopkins, Harvard, and Sanger Institute begin Arvados pilot projects.

Curoverse today announced their new open source platform Arvados is available for trial through a public beta. The software provides an infrastructure to manage, process, and share genomic and biomedical data in precision medicine development. “Arvados enables users to do science and medicine bioinformatics that is reproducible,” said CEO Adam Berrey. “Until now, this has been hard to achieve when working with petabytes of data, complex computations and pipelines that are constantly evolving.”

The company is implementing Arvados pilots at major medical and research institutions in the US and Europe including projects at Johns Hopkins University, Harvard Medical School, and the Wellcome Trust Sanger Institute.

Isaac Kohane, co-director at the Harvard Medical School Center for Biomedical Informatics commented: “It’s now possible to deliver more individually targeted medical care because we’re making sense of the molecular data that uniquely describe each patient. Precision medicine requires powerful new software infrastructure such as Arvados to handle the flood of new biomedical data.”

Arvados 1.0 is scheduled to be released in the summer of 2015. The company plans to offer the full commercial release of their on-premise and cloud solutions in the second half of 2015.

More on these topics